Anyone considering GLP-1 treatment should plan dose increases during recovery weeks, test all race nutrition during training while on the drug, and monitor training quality alongside the scale
Where can Canadian researchers access retatrutide
The first trial that tested a GLP-1 in a population with a mood disorder was published in January 2026 by Badulescu et al in Canada, to see if semaglutide (Ozempic) was a viable treatment of cognitive dysfunction in major depressive disorder (MDD), using 72 participants over the course of 16 weeks
Medical community engagement and professional education programs are building physician confidence in prescribing GLP-1 medications for obesity management
[DOI] [PMC free article] [PubMed] [Google Scholar] 128
Clinical trials and recent meta-analyses consistently show tirzepatide delivers the most substantial weight reduction among GLP-1 medications, with average losses of up to 22.5% of body weight